The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ERIC 2024 | Improving treatment access for patients with CLL in Taiwan
Shang-Ju Wu, MD, PhD, National Taiwan University Hospital, Taipei, Taiwan, discusses efforts to improve the availability and accessibility of novel treatments for patients with chronic lymphocytic leukemia (CLL) in Taiwan. Dr Wu highlights the challenges posed by limited access to novel agents compared to the U.S. and Europe but notes that clinical trial enrollment has been progressing well, including trials involving new compounds like BTK inhibitors. This interview took place at the 2024 European Research Initiative on CLL (ERIC) Meeting in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
